Leukemia, Myeloid, Acute
207
25
37
91
Key Insights
Highlights
Success Rate
71% trial completion
Published Results
50 trials with published results (24%)
Research Maturity
91 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
18.4%
38 terminated out of 207 trials
70.5%
-16.0% vs benchmark
8%
16 trials in Phase 3/4
55%
50 of 91 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 91 completed trials
Clinical Trials (207)
An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission
MB-dNPM1-TCR.1 in Relapsed/Refractory AML
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies
A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
CD34+ Transplants for Leukemia and Lymphoma
A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
Toxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation